Complete Commercialization

Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, chose EVERSANA  as their partner to make lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration (FDA) and subsequent BLA. Read the full story

“EVERSANA shares our tireless commitment to patients,” said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. “We’ve matched our dedication to research and development in COVID-19 with a proven commercialization partner to ensure lenzilumab will reach patients quickly and efficiently following a potential EUA.”

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has partnered with EVERSANA to commercialize margetuximab in the United States, if approved. Read The Full Story

“We are excited to partner with EVERSANA and leverage their integrated commercial services to efficiently launch margetuximab. We have been working closely with EVERSANA to fully align our commercialization strategies to educate healthcare providers and ensure patient access to margetuximab, while maintaining MacroGenics’ cash runway to fund our broader portfolio.”

EVERSANA to enhance market access, commercialization, and distribution activities of Solesta™ in the United States. Read the Full Story

“We have a remarkable opportunity to make a positive impact on the lives of millions of people worldwide. Solesta is an effective therapy that deserves the right commercial strategy to improve awareness among caregivers, enhance market access for patients, and provide important physician support services. These initiatives allow us the opportunity to drive a positive long term quality of life impact for those who are suffering every day. We are certain that EVERSANA has the right capabilities and team to meet the needs of our stakeholders,”

 James Leech, Head of Strategy & Corporate Development, Palette Life Sciences

EVERSANA to commercialize and distribute Gimoti in the U.S.  EVERSANA will utilize its internal sales organization along with other commercial functions for market access, marketing, distribution and patient support services. Read the full story

“We are excited to partner with EVERSANA, which will allow us to efficiently and rapidly prepare to commercialize Gimoti without the need to invest in a large corporate infrastructure and build out a sales force. Under the agreement, we will leverage EVERSANA’s integrated suite of capabilities, including highly experienced personnel with expertise in all key facets of pharmaceutical product commercialization.”

Dave Gonyer, President and CEO of EVOKE

EVERSANA, to commercialize and distribute Qtrypta™ in the United States. EVERSANA will utilize its internal sales force, distribution networks, patient services hub and market access capabilities to support the launch and commercialization of Qtrypta™. Read the full story.

“We are thrilled to partner with EVERSANA and, upon potential approval, look forward to leveraging its established sales force, distribution networks and market access capabilities to support the launch and commercialization of our innovative therapy for the acute treatment of migraine. With this collaboration, we now have access to a comprehensive commercial organization without the significant expense and time that would have been required to build our own infrastructure. We and EVERSANA have been working closely to ensure our commercialization strategies are aligned and fully supported with the appropriate resources to get this potential new therapy into the hands of patients who are in need of it.”

Steven Lo, President and CEO of Zosano